格隆汇8月15日丨创美药业(02289.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议（如 有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的 任何損失承擔任何責任。 嚴京斌 主席 Charmacy Pharmaceutical Co., Ltd. 創美藥業股份有限公司 中國汕頭，二零二五年八月十五日 （在中華人民共和國註冊成立之股份有限公司） （股份代號：2289） 董事會會議通告 創美藥業股份有限公司（｢本公司｣）董事會（｢董事會｣）謹此宣佈，董事會會議將於二 零二五年八月二十八日（星期四）舉行，藉以（其中包括）審議及批准本公司及其附屬 公司截至二零二五年六月三十日止六個月的中期業績及其發佈，並考慮宣派中期股息 （如有）。 承董事會命 創美藥業股份有限公司 於本公告日期，本公司執行董事為姚創龍先生、鄭玉燕女士與張寒孜女士；本公司非執 行董事為嚴京斌先生、付征女士與徐飛先生；及本公司獨立非執行董事為李漢國先生、 尹智偉先生與關鍵先生（又名關蘇哲）。 ...

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創美藥業股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02289 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | 本月底法定/註冊股本總額： RMB 108,000,000 備註： 因本 ...

Company Performance - The company ranked 35th among the top 100 wholesale enterprises in China based on revenue from its principal business in 2023[3]. - The company ranked 6th among pharmaceutical distribution businesses in Guangdong Province[3]. - For the year ended December 31, 2024, the Group's operating revenue increased by 0.72% to RMB 4,435.46 million from RMB 4,403.63 million in 2023[22]. - Gross profit rose by 10.94% to RMB 324.76 million, with a gross profit margin increase from 6.65% in 2023 to 7.32% in 2024[22]. - Net profit attributable to shareholders of the parent company increased by 3.78% to RMB 53.28 million from RMB 51.34 million in 2023[22]. - The total operating revenue for the year ended December 31, 2024, was RMB 4,435.5 million, representing a slight increase from RMB 4,403.6 million in 2023[38]. - The net profit attributable to shareholders of the parent company for 2024 was RMB 53.3 million, up from RMB 51.3 million in 2023, indicating a growth of approximately 3.8%[38]. - The total assets as of December 31, 2024, reached RMB 3,456.6 million, an increase from RMB 3,247.7 million in 2023, reflecting a growth of about 6.4%[38]. Market Position and Strategy - The company has been recognized as an Excellent Pharmaceutical Logistics and Distribution Enterprise for four consecutive years and has received multiple awards for its logistics capabilities[5]. - The company has been consistently ranked among the "Guangdong Top-500 Enterprises" and the "Top-100 Wholesalers in the Pharmaceutical Distribution Industry" for over a decade[24]. - The Group aims to strengthen its competitive edge through the establishment of Guangdong Charmacy Pharmaceutical Logistics Co., Ltd. in June 2024, focusing on domestic freight forwarding services[20]. - The Group plans to focus on the non-bidding market and build a high-quality development path in 2025, enhancing its logistics distribution system and third-party logistics service competitiveness[27]. - The Group's strategy includes leveraging artificial intelligence and big data to enhance operational efficiency and meet evolving pharmaceutical distribution needs[28]. - The company aims to enhance competitiveness in third-party logistics services by leveraging artificial intelligence for operational decision-making[32]. - The company is committed to exploring high-quality development pathways and unlocking new profit engines for sustainable growth[32]. Digital Transformation and Innovation - The pharmaceutical distribution industry in China is experiencing profound changes, shifting towards supply chain management, digital operations, and professional services[20]. - The pharmaceutical distribution industry is transitioning towards a model focused on supply chain management, digital operations, and professional services[41]. - The digital transformation of pharmaceutical distributors is being driven by regulatory constraints and medical insurance policies, further deepening their operational capabilities[59]. - The company aims to achieve intelligent management of the entire process and improve efficiency through the integration of digitalization and AI technology[96]. - The Group is leveraging digital technologies to improve service capabilities in the pharmaceutical supply chain, enhancing the "last mile" service through advanced technologies like big data and AI[87]. - The company is exploring AI applications to enhance operational efficiency, with successful automation upgrades in financial management and logistics[72]. - The company aims to establish an end-to-end intelligent business ecosystem through full-process digital integration and continuous iteration of AI models[73]. Logistics and Distribution Network - The company operates a modern information system covering the entire pharmaceutical distribution supply chain, including procurement, sales, warehousing, transportation, and delivery[3]. - The company has established a highly efficient delivery mechanism, providing three deliveries per day within a 10-kilometer radius[3]. - The company has four modern pharmaceutical logistics centers and a professional marketing service team[3]. - The Group established a large pharmaceutical sorting and distribution centre in Shenzhen, enhancing its influence in the Greater Bay Area's pharmaceutical terminal market and promoting the coordinated upgrading of the regional pharmaceutical industry chain[76]. - The Group's logistics network adheres to unified Good Supply Practice (GSP) management standards, ensuring standardized storage conditions and enhancing service quality[77]. - The Group's third-party pharmaceutical logistics business saw a year-on-year increase of 30% in the number of clients and over 55% growth in corresponding revenue as of December 31, 2024[81]. Customer and Supplier Relationships - As of December 31, 2024, the Group's distribution network covered 14,429 customers, including 13,744 pharmaceutical retail customers, and collaborated with 1,206 suppliers[19]. - The company has strengthened cooperation with 1,206 suppliers, including 623 pharmaceutical manufacturers and 583 distributor suppliers, representing an increase of 60 suppliers compared to last year[65]. - The company distributed 12,810 product specifications as of December 31, 2024, an increase from 12,212 in 2023, with 4,759 being Chinese patent medicines and 4,664 Western medicines[66][65]. Financial Management and Costs - Operating costs remained stable at RMB 4,110.70 million for 2024, slightly down from RMB 4,110.89 million in 2023[114]. - Selling expenses decreased by 1.65% to RMB 120.44 million in 2024, compared to RMB 122.47 million in 2023[122]. - Management expenses increased by 15.33% to RMB 54.82 million in 2024, primarily due to increased employee compensation expenses[123]. - Finance costs surged by 47.09% to RMB 62.29 million in 2024, driven by increased bank loans and corresponding interest expenses[124]. - Income tax expenses rose by 11.40% to RMB 17.91 million in 2024, up from RMB 16.07 million in 2023[125]. Leadership and Governance - The company has a diverse leadership team with extensive experience in finance, management, and the pharmaceutical industry, enhancing its strategic decision-making capabilities[182]. - The Group is focused on expanding its market presence and enhancing product management through experienced leadership[176]. - The leadership team is well-equipped to navigate the complexities of the pharmaceutical market, leveraging their combined expertise for strategic initiatives[190].

Core Viewpoint - In 2024, Chuangmei Pharmaceutical achieved significant growth in revenue and net profit, driven by the dual forces of policy deepening and digital transformation in the Chinese pharmaceutical distribution industry, alongside an expanding retail market and diversified services [1][2]. Financial Performance - For the year ending December 31, 2024, Chuangmei Pharmaceutical reported a revenue of RMB 4.435 billion and a net profit of RMB 53.28 million, both showing year-on-year growth compared to 2023 [1]. - The basic and diluted earnings per share increased to RMB 0.4934, with a proposed final dividend of RMB 0.45 per share, representing a high payout ratio of 91% [1]. Business Development - The company established a comprehensive industrial chain and commercial ecosystem by collaborating with well-known pharmaceutical companies such as China Resources Sanjiu, Helion, and Guangzhou Pharmaceutical Baiyunshan [2]. - As of December 31, 2024, Chuangmei Pharmaceutical distributed 12,810 products through a network covering 14,429 customers, with 1,206 suppliers, all showing stable growth from 2023 [2]. Logistics and Supply Chain - The company launched a new pharmaceutical logistics center in Shenzhen, enhancing multi-warehouse collaboration and cross-regional distribution, which reduced logistics costs and ensured drug quality [3]. - Chuangmei Pharmaceutical's third-party logistics business saw a 30% increase in customer numbers and over 55% growth in related revenue, marking a significant milestone in its logistics operations [3]. Technological Innovation - The company is exploring AI applications in business processes, achieving partial automation and establishing an intelligent workflow engine to enhance operational efficiency [4]. - Future plans include a comprehensive digital integration of processes, leveraging AI for resource optimization and decision-making, thereby enhancing overall operational effectiveness and core competitiveness [4]. Strategic Outlook - Chuangmei Pharmaceutical aims to deepen its market presence in Guangdong and surrounding areas, aspiring to become a leading competitive player in the pharmaceutical health services sector in China [4]. - The company plans to capitalize on digital and intelligent transformation opportunities in the pharmaceutical industry, focusing on AI technology integration and expanding its product offerings through strategic partnerships [4].

Financial Performance - For the year ending December 31, 2024, the group's operating revenue was RMB 4,435.46 million, an increase of 0.72% compared to RMB 4,403.63 million in 2023[4] - The net profit for the year 2024 was RMB 53.28 million, reflecting a growth of 3.78% from RMB 51.34 million in 2023[4] - The basic and diluted earnings per share for 2024 were RMB 0.4934, up from RMB 0.4754 in 2023[4] - Revenue from main business operations reached RMB 4,385,119,653.22 for the year ending December 31, 2024, compared to RMB 4,347,522,184.54 in 2023, reflecting a growth of approximately 0.9%[27] - Total revenue for the year was RMB 4,435,460,674.85, slightly up from RMB 4,403,633,478.08 in the previous year, indicating an increase of about 0.7%[27] - The gross profit increased by 10.94% to RMB 324.76 million for the year ending December 31, 2024, compared to RMB 292.74 million in 2023, with the gross margin rising from 6.65% to 7.32%[83] Assets and Liabilities - Total assets as of December 31, 2024, amounted to RMB 3,456.64 million, compared to RMB 3,247.66 million as of December 31, 2023[7] - Current assets totaled RMB 3,029.99 million as of December 31, 2024, an increase from RMB 2,811.99 million in 2023[7] - Total liabilities increased to RMB 2,837,952,734.34 as of December 31, 2024, up from RMB 2,649,849,020.30 in 2023, representing a growth of approximately 7.1%[8] - Current liabilities totaled RMB 2,788,603,021.09, an increase from RMB 2,618,858,000.99 in the previous year, marking a rise of about 6.5%[8] - Shareholders' equity totaled RMB 618,690,947.99 as of December 31, 2024, compared to RMB 597,806,856.30 in 2023, representing an increase of approximately 3.1%[8] Cash Flow and Financial Position - Cash and cash equivalents decreased to RMB 563.15 million in 2024 from RMB 634.20 million in 2023[7] - The company reported a net profit increase in retained earnings, with undistributed profits rising to RMB 200,556,936.21 from RMB 181,154,889.21, a growth of about 10.5%[8] - The group's current ratio improved to 1.09 as of December 31, 2024, compared to 1.07 as of December 31, 2023[90] - The group's capital debt ratio increased to 51.37% as of December 31, 2024, from 44.28% as of December 31, 2023[97] Expenses - The group's total operating costs for 2024 were RMB 4,358.59 million, compared to RMB 4,332.54 million in 2023[5] - Sales expenses decreased by 1.65% to RMB 120.44 million for the year ending December 31, 2024, from RMB 122.47 million in 2023[84] - Management expenses increased by 15.33% to RMB 54.82 million for the year ending December 31, 2024, primarily due to new personnel and training investments[85] - Financial expenses rose by 47.09% to RMB 62.29 million for the year ending December 31, 2024, attributed to increased bank borrowings and related interest costs[86] Accounts Receivable and Payable - The company reported a significant increase in accounts receivable, rising to RMB 1,163.24 million in 2024 from RMB 961.72 million in 2023[7] - Accounts receivable increased to RMB 1,184,455,239.82 at year-end from RMB 982,891,686.13 at the beginning of the year, with a net amount of RMB 1,163,237,552.39 after deducting bad debt provisions[40] - The company recorded a bad debt provision of RMB 21,217,687.43 for accounts receivable, slightly up from RMB 21,172,836.07 at the beginning of the year[40] - The year-end balance of accounts payable totaled RMB 387,825,713.54, down from RMB 659,073,566.35 at the beginning of the year, indicating a decrease of approximately 41%[49] Market and Industry Insights - The pharmaceutical distribution market in China is projected to grow to RMB 4 trillion by 2028, with a compound annual growth rate of 7%[53] - The retail pharmacy market is expected to reach RMB 574 billion in 2024, showing a year-on-year growth of 3.7%[55] - The online pharmaceutical market in China has reached a sales figure of over RMB 60 billion in 2023, reflecting a year-on-year growth of 28.46%[74] Strategic Initiatives - The company is leveraging new technologies such as big data and AI to enhance service capabilities and meet evolving market demands[57] - The company aims to build a comprehensive marketing ecosystem by closely collaborating with upstream and downstream partners, enhancing brand value and market effectiveness[64] - The company is committed to a digital transformation strategy, focusing on end-to-end intelligent business closed-loop construction through continuous iteration of AI models[66] - The company has established modern pharmaceutical distribution centers in Guangzhou, Shantou, Shenzhen, and Zhuhai, equipped with advanced logistics networks and information systems[69] Governance and Compliance - The company has adhered to the corporate governance code as per the listing rules for the year ending December 31, 2024, and will continue to review its governance practices[109] - All directors and supervisors have complied with the standard code for securities transactions during the year ending December 31, 2024[110] - The audit committee, consisting of three members, has reviewed the accounting principles and policies adopted by the group for the year ending December 31, 2024[112]

Company Recognition and Awards - In the first half of 2024, the Group was recognized as an Excellent Pharmaceutical Logistics and Distribution Enterprise for four consecutive years[1] - The Group has received multiple awards, including the Best Pharmaceutical Cold Chain Logistics Centre for six consecutive years[1] - The Company has been awarded the China Logistics Industry "Golden Ant" Innovation Award for seven consecutive years[1] Market Position and Revenue - The Company ranked 35th among the top 100 wholesalers in China based on revenue generated from its principal business in 2023[1] - The Company ranked 6th among pharmaceutical distribution enterprises in Guangdong Province[1] - Operating revenue for the six months ended June 30, 2024, was RMB 2,347,185, representing a year-on-year increase of 3.44% compared to RMB 2,269,074 in 2023[25] - Revenue from principal business reached RMB 2,325,460, up from RMB 2,241,971 in the previous year, indicating a growth of 3.7%[57] - Revenue from distributors was RMB 1,093,126, slightly up from RMB 1,076,993, while revenue from retail pharmacy stores increased to RMB 1,151,208 from RMB 1,085,417[57] Financial Performance - Total profit for the same period was RMB 38,928, reflecting a year-on-year growth of 10.72% from RMB 35,157 in 2023[25] - Net profit attributable to the shareholders of the parent company was RMB 26,747, a slight increase of 1.50% from RMB 26,353 in 2023[25] - Basic and diluted earnings per share for the six months ended June 30, 2024, were RMB 0.2477, up 1.50% from RMB 0.2440 in 2023[25] - The Group's gross profit increased by 18.85% from RMB 142.35 million for the six months ended June 30, 2023, to RMB 169.18 million for the same period in 2024[61] - The gross profit margin rose from 6.27% to 7.21% due to a 58.49% year-on-year increase in third-party logistics revenue and adjustments in product mix[61] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 3,270,652, showing a 0.71% increase from RMB 3,247,656 as of December 31, 2023[26] - Total liabilities increased by 1.08% to RMB 2,678,497 as of June 30, 2024, compared to RMB 2,649,849 at the end of 2023[26] - Shareholders' equity decreased by 0.95% to RMB 592,154 as of June 30, 2024, down from RMB 597,807 at the end of 2023[26] Distribution Network and Product Range - As of June 30, 2024, the distribution network covered 12,794 customers, an increase of 532 compared to the same period last year, including 611 distributors and 8,516 retail pharmacy stores[36] - The company distributed 11,596 types of products, representing an increase of 838 products compared to the same period last year, with a total of 1,052 suppliers[36] - The total number of products increased to 11,596 for the six months ended June 30, 2024, compared to 10,758 in the same period of 2023, representing a growth of approximately 7.8%[37] Industry Trends and Market Outlook - The pharmaceutical distribution market in China is projected to exceed RMB 4 trillion by 2028, with a compound growth rate of 7%[27] - The out-of-hospital market is expected to reach RMB 1.6 trillion by 2029, potentially matching or exceeding the in-hospital market[29] - The pharmaceutical distribution industry is moving towards high-quality development, with increasing industry concentration and deepening professional services[29] - The ongoing healthcare reforms in China are expected to significantly impact the pharmaceutical industry, shifting the focus from treating diseases to prioritizing people's health[48] Digital Transformation and Technology Integration - The integration of emerging technologies such as AI, big data, and cloud computing is accelerating the digitalisation of the pharmaceutical distribution industry[30] - The Group aims to leverage digital technologies to improve efficiency and quality across the entire pharmaceutical supply chain, including R&D, production, distribution, and service[48] - The focus on digital transformation in the pharmaceutical industry will enhance brand promotion and marketing capabilities[49] Strategic Initiatives and Future Plans - The Company adheres to a development strategy of "Intensive Engagement in Guangdong Province and Extensive Coverage across Surrounding Areas"[1] - The company plans to deepen strategic cooperation with brand manufacturers to capture growth opportunities in non-tendering market products[51] - The company aims to enhance its logistics capabilities and expand third-party logistics business to improve operational efficiency[51] - The Group plans to strengthen risk management and improve operational quality to ensure continuous competitiveness[49] Governance and Compliance - The Company complied with the Corporate Governance Code during the reporting period, with ongoing reviews to enhance governance standards[87] - The Audit Committee has reviewed the unaudited interim results for the six months ended June 30, 2024, ensuring compliance with applicable accounting standards[103] - The Group's financial statements are prepared according to the Accounting Standards for Business Enterprises promulgated by the Ministry of Finance[131] Cash Flow and Financial Management - Cash flow from operating activities showed a net outflow of RMB 174,686,709.65, an improvement compared to the outflow of RMB 228,779,953.32 in the prior period[116] - Cash received from sales of goods and services amounted to RMB 2,016,748,960.28, up from RMB 1,819,538,031.52, marking an increase of about 10.9%[116] - The Group continues to assess its customers' credit and financial positions to minimize credit risks and maintain a sound liquidity position[72] Shareholder Information - The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with the interim dividend of 2023, which was also nil[86] - As of June 30, 2024, Mr. Yao Chuanglong held 34,530,000 H Shares, representing approximately 31.97% of the total issued share capital of 108,000,000 H Shares[92][94] - Ms. You Zeyan holds a beneficial interest in 29,050,000 H Shares, representing approximately 26.90% of the total issued share capital[99] Accounting Policies and Financial Reporting - The Group's accounting policies are aligned with the Accounting Standards for Business Enterprises, ensuring accurate financial reporting[3] - The Group recognizes income when the customer gains control over goods or services, typically three days after shipment[185] - The Group recognizes deferred income tax assets for all unutilized deductible losses within the limit of sufficient taxable income[190]

Financial Performance - The company's operating revenue for the six months ended June 30, 2024, was RMB 2,347,185,000, representing a year-on-year increase of 3.44% compared to RMB 2,269,074,000 in the same period of 2023[1]. - The total profit for the period was RMB 38,928,000, an increase of 10.72% from RMB 35,157,000 in the previous year[1]. - Net profit attributable to shareholders of the parent company was RMB 26,747,000, reflecting a year-on-year growth of 1.50% from RMB 26,353,000[1]. - Basic and diluted earnings per share were RMB 0.2477, up from RMB 0.2440, marking a 1.50% increase[1]. - The company's main business revenue for the six months ended June 30, 2024, was RMB 2,325.46 million, an increase of 3.71% from RMB 2,241.97 million for the same period in 2023[60]. - The company's operating income for the six months ended June 30, 2024, was RMB 2,347.18 million, up 3.44% from RMB 2,269.07 million in the previous year[61]. - Gross profit increased by 18.85% to RMB 169.18 million for the six months ended June 30, 2024, compared to RMB 142.35 million for the same period in 2023, with the gross margin rising from 6.27% to 7.21%[62]. - Net profit increased by 1.50% from RMB 26.35 million for the six months ended June 30, 2023, to RMB 26.75 million for the six months ended June 30, 2024, primarily due to stable growth in core business[67]. Operating Costs and Expenses - Total operating costs for the period were RMB 2,303,414,000, compared to RMB 2,231,021,000 in the same period last year[3]. - Financial expenses increased significantly to RMB 34,102,000 from RMB 17,786,000, primarily due to higher interest expenses[3]. - The company's sales expenses remained stable at RMB 62.88 million for the six months ended June 30, 2024, a slight decrease of 0.10% from RMB 62.94 million in the previous year[63]. - Management expenses increased by 23.12% to RMB 23.33 million for the six months ended June 30, 2024, compared to RMB 18.95 million for the same period in 2023[64]. - Financial expenses surged by 91.74% to RMB 34.10 million for the six months ended June 30, 2024, primarily due to an increase in short-term borrowings[65]. - Income tax expenses rose by 38.34% to RMB 12.18 million for the six months ended June 30, 2024, compared to RMB 8.80 million for the same period in 2023[66]. Assets and Liabilities - As of June 30, 2024, total assets amounted to RMB 3,270,651,527.39, an increase from RMB 3,247,655,876.60 as of December 31, 2023, reflecting a growth of approximately 0.7%[7][9]. - Current assets totaled RMB 2,832,717,939.94, slightly up from RMB 2,811,999,921.54, indicating a growth of about 0.7%[7]. - The company's cash and cash equivalents decreased to RMB 404,288,707.41 from RMB 634,197,229.09, representing a decline of approximately 36.2%[7]. - Total liabilities increased to RMB 2,678,497,435.56 from RMB 2,649,849,020.30, marking a rise of about 1.1%[9]. - The company's total equity decreased to RMB 592,154,091.83 from RMB 597,806,856.30, reflecting a decline of about 1.0%[9]. - The debt-to-capital ratio increased to 52.96% as of June 30, 2024, from 44.28% as of December 31, 2023[74]. Accounts Receivable and Payable - The accounts receivable balance as of June 30, 2024, was approximately $1.06 billion, an increase from $982.9 million as of December 31, 2023, indicating a growth of 7.9%[31]. - The net accounts receivable after provisions for bad debts was approximately $1.04 billion as of June 30, 2024, compared to $961.7 million at the end of 2023, showing an increase of 8.5%[31]. - The total accounts payable as of June 30, 2024, is approximately $513.25 million, a decrease of about 22.1% from $659.07 million as of December 31, 2023[40]. - Accounts payable within one year account for approximately 98.5% of the total, with a balance of about $507.13 million[41]. Market and Strategic Focus - The company continues to focus on expanding its market presence and enhancing product development strategies[2]. - The company is positioned to benefit from the ongoing transformation in China's healthcare sector, focusing on high-quality development and increased demand for pharmaceutical services[42]. - The overall pharmaceutical distribution market is steadily growing, with a shift towards retail and outpatient markets due to recent healthcare reforms[45]. - The company aims to deepen strategic cooperation with brand manufacturers to capture growth opportunities in non-tender market products[57]. - The company is actively seeking domestic and international industry cooperation opportunities to promote high-quality development and optimize its product supply chain[59]. Logistics and Distribution - The establishment of the Shenzhen Pharmaceutical Logistics Center aims to enhance the company's influence in the Greater Bay Area and is strategically significant for logistics network deployment in Guangdong Province[51]. - The company achieved a year-on-year increase of over 22% in the number of clients for third-party logistics services and a revenue growth of over 58%[51]. - Guangdong Chuangmei Pharmaceutical Logistics Co., Ltd. was established to promote the company's third-party logistics business towards scale, standardization, and intelligence[52]. - The company is focused on digital and intelligent transformation in the pharmaceutical industry, leveraging advanced technologies like big data and AI to enhance efficiency across the supply chain[53]. Dividend and Investments - The company did not declare an interim dividend for the six months ended June 30, 2024, maintaining the same stance as in 2023[25]. - There were no significant investments or acquisitions during the reporting period[77][79].

Company Performance - Charmacy Pharmaceutical Co., Ltd. ranked 38th among the top 100 wholesale enterprises in China based on revenue from its principal business in 2022[3]. - The company achieved a gross revenue of RMB 271.76 million in 2022, reflecting a significant increase from previous years[10]. - In 2023, the company's revenue reached RMB 292.74 million, with a gross profit margin increasing to 6.65% from 6.51% in 2022[18]. - The total operating revenue reached RMB 4,403,633, an increase from RMB 4,175,279 in 2022, representing a growth of approximately 5.5%[28]. - The total profit for 2023 was RMB 67,420, a decrease from RMB 122,054 in 2022, indicating a decline of about 44.9%[28]. - Net profit attributable to shareholders of the parent company was RMB 51,345 in 2023, down from RMB 90,472 in 2022, reflecting a decrease of approximately 43.2%[28]. - The Group's operating revenue for the year ended December 31, 2023, was RMB 4,403.63 million, an increase of 5.47% from RMB 4,175.28 million for the year ended December 31, 2022[168]. - The principal business revenue amounted to RMB 4,347,522,000, up from RMB 4,140,664,000 in the previous year, reflecting a growth of 5.0%[108]. Logistics and Distribution - The company operates a B2B e-commerce platform "Charmacy e-Medicine" for online ordering, inquiries, and payments[3]. - The logistics system includes a highly efficient delivery mechanism with multiple daily deliveries within specified radii[3]. - The company has received multiple awards for its logistics capabilities, including the Best Pharmaceutical Cold Chain Logistics Centre for five consecutive years[5]. - The company has established medium and large modern pharmaceutical distribution centers in Shantou, Guangzhou, Zhuhai, and Huizhou, equipped with advanced logistics technology to ensure quality and safety of pharmaceuticals[140]. - The company emphasizes the importance of high-quality management and operational excellence in selecting contractors for third-party logistics services[140]. - The Group's third-party pharmaceutical logistics commissioning business saw a year-on-year increase of over 36% in the number of customers and over 72% in corresponding revenue as of December 31, 2023[143]. Market Trends and Strategies - The pharmaceutical distribution market in China is expected to exceed RMB 4 trillion by 2028, with a compound growth rate of 7%[33]. - The company aims to understand market pattern changes and explore industrial chain demands as key strategies for stable growth and high-quality development[23]. - The company plans to leverage competitive advantages in the non-bidding market and enhance digital transformation to drive high-quality development in 2024[24]. - The company aims to improve service quality and create new channels in the pharmaceutical distribution industry to generate long-term value for shareholders[24]. - The company is committed to leveraging digital technology to optimize supply chain logistics and improve last-mile service capabilities[150]. - The company plans to actively seek domestic and international industrial cooperation opportunities to promote high-quality development[156]. Financial Position - The total assets increased to RMB 3,247,656 in 2023 from RMB 2,866,465 in 2022, marking a growth of about 13.3%[28]. - Total liabilities rose to RMB 2,649,849 in 2023, compared to RMB 2,271,403 in 2022, which is an increase of approximately 16.6%[28]. - The gearing ratio increased to 44.28% as of December 31, 2023, compared to 42.75% in the previous year[163]. - Cash and bank deposits increased to RMB112.93 million as of December 31, 2023, from RMB68.86 million as of December 31, 2022[172]. - The Group's net current assets were RMB193.14 million as of December 31, 2023, compared to RMB206.77 million as of December 31, 2022, with a current ratio of 1.07[172]. Governance and Management - The Board resolved on May 31, 2023, to elect Mr. Yan Jingbin as the chairman, replacing Mr. Yao, improving the governance structure[59]. - The responsibilities of the chairman and the CEO are separated to ensure effective checks and balances in governance[72]. - The Company established a nomination committee on November 26, 2015, in accordance with the corporate governance code[72]. - The Company has adopted a Director nomination policy to ensure diversity and suitability of candidates for the Board[75]. - The Audit Committee held two meetings on March 31, 2023, and August 25, 2023, to review the Group's annual results for the year ended December 31, 2023, and interim results for the six months ended June 30, 2023[82]. Employee and Gender Diversity - The board consists of three female directors and six male directors, achieving gender diversity in compliance with the listing rules[106]. - As of December 31, 2023, the company had 451 male employees and 380 female employees, with a gender ratio of 54% male and 46% female[105]. - The company is committed to maintaining and enhancing gender diversity within its workforce[105]. Regulatory Environment - The implementation of the Specification for Logistics Service of Medicinal Product (GB/T 30335-2023) on September 7, 2023, aims to standardize logistics service operations and promote the digital and intelligent transformation of logistics in the pharmaceutical industry[36]. - The New Regulations for pharmaceutical storage and transportation came into effect on July 1, 2023, enhancing the regulatory framework for logistics enterprises[120][125]. - The National Medical Products Administration released a draft guidance in October 2023 to promote the standardization of newly established pharmaceutical wholesale enterprises and third-party logistics, indicating a significant restructuring in the traditional pharmaceutical supply chain[40].